Impact of glucocorticoid receptor gene (NR3C1) polymorphisms in Turkish patients with metabolic syndrome

Kaya, Zehra; Çağlayan, Suat; Akkiprik, Mustafa; Aral, Cenk; Özışık, Gökhan; Özata, Metịn; Özer, Ali Haydar

doi:10.1007/s40618-015-0409-1

Cited by 16 publications

(13 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Likewise, it was recently reported in a Turkish population that the frequency of N363S G allele carriers was 0.5% [29]. In contrast to our results, in Europe, the frequency of carrying at least one G allele of the N363S polymorphism was reported to range from 4% to 9% [26,28], highlighting the ethnic factors in its carriage.…”

Section: Discussioncontrasting

confidence: 73%

“…The differences between our results and those of Marino et al [24] may be due to ethnic and genetic differences. Both N363S and BclI polymorphisms are known to make patients more prone to the side effects of the GCs [28,29,30,31]. The effects of GR gene mutations and polymorphisms on treatment success and drug resistance were also recently investigated and controversial results were obtained [3,20,21,26].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Association Between N363S and BclI Polymorphisms of the Glucocorticoid Receptor Gene (NR3C1) and Glucocorticoid Side Effects During Childhood Acute Lymphoblastic Leukemia Treatment

Cihan¹,

Karabulut²,

Kutlay³

et al. 2017

Tjh

View full text Add to dashboard Cite

Objective:Glucocorticoids (GCs) are the key drugs for the treatment of pediatric acute lymphoblastic leukemia (ALL). Herein, investigation of the relationship between the N363S and BclI polymorphisms of the GC receptor gene (NR3C1) and the side effects of GCs during pediatric ALL therapy was aimed.Materials and Methods:N363S and BclI polymorphisms were analyzed in 49 patients with ALL treated between 2000 and 2012. The control group consisted of 46 patients with benign disorders. The side effects of GCs noted during the induction and reinduction periods were evaluated retrospectively according to the National Cancer Institute’s Common Terminology Criteria for Adverse Events, version 4.0.Results:The BclI allele and genotype frequencies were found similar in the two groups. No N363S polymorphism was detected in either of the groups. During induction, dyspepsia was found more frequently in the CG than in the CC (wild-type) genotype (36.4% vs. 5.3%, p=0.018) and depression symptoms more frequent in patients with the G allele (CG+GG) than the CC genotype (39.3% vs. 10.5%, p=0.031). During reinduction, Cushingoid changes, dyspepsia, and depression symptoms were more frequent in patients with the G allele (CG+GG) than in patients with the CC genotype (48.1% vs. 17.6%, p=0.041; 29.6% vs. 0.0%, p=0.016; 40.7% vs. 11.8%, p=0.040, respectively).Conclusion:In our study, patients with the BclI polymorphism were found to have developed more frequent side effects. We think that the BclI polymorphism should be considered while designing individualized therapies in childhood ALL.

show abstract

Section: Discussioncontrasting

confidence: 73%

Section: Discussionmentioning

confidence: 99%

Association Between N363S and BclI Polymorphisms of the Glucocorticoid Receptor Gene (NR3C1) and Glucocorticoid Side Effects During Childhood Acute Lymphoblastic Leukemia Treatment

Cihan¹,

Karabulut²,

Kutlay³

et al. 2017

Tjh

View full text Add to dashboard Cite

show abstract

“…Allele frequencies were calculated from genotype data as it is given in Table 2, and it is revealed that the polymorphic allele frequency is significantly higher in patients than in controls (51.8% and 37.8%, respectively) (p=0.010). Polymorphic allele frequency of our healthy group (0.378) is similar to previous data from Turkish population [14], and close to European population data [13]. There were no significant correlations found between genotype frequencies and clinical variables of the patients ( Table 3).…”

Section: Tth111i (Rs10052957)supporting

confidence: 89%

“…It is 0.297 in our healthy group and slightly lower than European data. On the other hand, polymorphic allele frequency is close to our previous data from Turkish individuals [14].…”

Section: Bcli (Rs41423247)supporting

confidence: 88%

See 1 more Smart Citation

Glucocorticoid receptor gene polymorhisms and breast cancer: significant association in cancerous tissue samples from Turkish patients

Akyıldız

Akkiprik

Özer

et al. 2018

Preprint

View full text Add to dashboard Cite

Background and Aims: Glucocorticoid receptor (GR) has been postulated to serve an important role in normal breast and breast carcinoma. On the other hand, studies on its common polymorphisms with breast cancer are very limited. In this study, we aimed to assess the presence and frequency of 4 common polymorphisms of the GR gene in the cancerous tissue samples from breast cancer patients in the Turkish population and compare them with healthy individuals. Methods: DNA samples from 86 Turkish female breast cancer patients and 86 healthy controls analysed for BclI, Tth111I, N363S and ER22/23EK polymorphisms of GR gene by PCR-RFLP. Results: N363S polymorphism was not observed in study samples. Frequency of BclI polymorphism did not differ between cases and controls but it associated with family history of cancer. The polymorphic allele frequency of Tth111I and ER22/23EK was found to be higher in cases compared to healthy samples (p<0.05). Also, a haplotype containing polymorphic variants of these two polymorphisms found to be associated with breast cancer. Conclusion: The data presented here suggest that polymorphisms of GR gene may be an important risk factor for breast cancer predisposition.

show abstract

Drug-induced hyperglycaemia and diabetes: pharmacogenomics perspectives

Liu

et al. 2018

Arch. Pharm. Res.

View full text Add to dashboard Cite

Drug-induced diabetes is widely reported in clinical conditions, and it is becoming a global issue because of its potential to increase the risk of severe cardiovascular complications. However, which drug mechanisms exert their diabetogenic effects and why the effects present significant inter-individual differences remain largely unknown. Pharmacogenomics, which is the study of how genomic variation influences drug responses, provides an explanation for individual differences in drug-induced diabetes. We highlight that pharmacogenomics can be involved in regulating the expression of genes in signaling pathways related to the pharmacokinetics or pharmacodynamics of drugs or the pathogenesis of diabetes, contributing to the differences in drug-induced glucose impairment. The pharmacogenomics studies of the major diabetogenic drugs are reviewed, including calcineurin inhibitors, antipsychotics, hormones, and antihypertensive drugs. We intend to elucidate the genetic basis of drug-induced diabetes and pave the way for the precise use of these drugs in the clinic.

show abstract

Impact of glucocorticoid receptor gene (NR3C1) polymorphisms in Turkish patients with metabolic syndrome

Cited by 16 publications

References 35 publications

Association Between N363S and BclI Polymorphisms of the Glucocorticoid Receptor Gene (NR3C1) and Glucocorticoid Side Effects During Childhood Acute Lymphoblastic Leukemia Treatment

Association Between N363S and BclI Polymorphisms of the Glucocorticoid Receptor Gene (NR3C1) and Glucocorticoid Side Effects During Childhood Acute Lymphoblastic Leukemia Treatment

Glucocorticoid receptor gene polymorhisms and breast cancer: significant association in cancerous tissue samples from Turkish patients

Drug-induced hyperglycaemia and diabetes: pharmacogenomics perspectives

Contact Info

Product

Resources

About